About the Company
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. In September 2019, Zymeworks announced that, following their clinical trials, it has been confirmed that their ZW25 monotherapy can provide durable disease control in patients with a variety of HER2-expressing solid tumors that have progressed following standard of care treatments. In May 2022, Zymeworks rejected an unsolicited takeover proposal from a Dubai hedge fund, All Blue Falcons FZE, an arm of All Blue Capital.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ZYME News
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Zymeworks' Zanidatamab is in phase 3 clinical trials and has significant market potential for biliary tract cancer. Learn ...
ZYME ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Zymeworks Inc.
NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc.
Levi & Korsinsky Reminds Shareholders of an Investigation into Zymeworks Inc. (ZYME) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of ...
Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
A downtrend has been apparent in Zymeworks Inc. (ZYME) lately with too much selling pressure. The stock has declined 13.4% over the past four weeks. However, given the fact that it is now in oversold ...
Opinion: The Next Generation of ADCs Will Improve Cancer Treatment
Researchers are working to optimize the properties of antibody-drug conjugates in order to maximize clinical efficacy while ...
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat ...
Loading the latest forecasts...